Taking stock of the drug industry, from the lab to the medicine chestDecember 6, 2023Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents The FTC letters sent to the drugmakers were not empty threats, a source explained, adding the agency is prepared to file lawsuits. By Ed Silverman STAT+ | U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues The Association for Accessible Medicine had filed a lawsuit claiming the law amounted to an "unconstitutional overreach." By Ed Silverman STAT+ | Pfizer plans to depart BIO The pharmaceutical giant Pfizer plans to exit BIO, the latest in a string of major departures from industry trade groups. By Rachel Cohrs Cydni Elledge/The New York Times STAT+ | Opinion: A bold approach to pay for weight loss drugs for everyone who needs them Medicare is facing disaster in the form of metabolic disease. New weight loss drugs like Wegovy can help, with a new approach to pricing. By Jeremy L. Shane STAT+ | CVS's new drug payment plan won't lower patients' prices, experts warn Drug pricing experts say the CVS CostVantage program appears designed to pad CVS' own bottom line rather than making prescription drugs cheaper. By Tara Bannow More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments